About this trial
Despite the increasing availability and advances in the analysis of high-throughput DNA sequencing, the majority of patients with early-onset or familial parkinsonism remain without a molecular diagnosis.
Studying the genetic forms of parkinsonian syndromes presents numerous clinical, scientific and therapeutic interests. In clinical practice, identifying the genetic cause in a patient allow to provide genetic counseling and estimate the risk of recurrence in their relatives. Establishing correlations between the genotype and phenotype of patients with genetically determined parkinsonism, allow to better anticipate the evolution of the disease, or even to highlight biomarkers during the presymptomatic phases. Finally, the proteins encoded by the genes implicated in familial parkinsonism represent potential therapeutic targets likely to be modulated by neuroprotective pharmacological agents, even in sporadic Parkinson's disease.
In this work,investigators aimed at elucidating the missing genetic causes of parkinsonism through the application of combined RNA and whole genome sequencing.
Eligibility criteria
Qualifiers
Dopaminergic denervation proven by ioflupane brain scintigraphy (DaTscan®)
DNAs from both asymptomatic parents available in biobank
Subject affiliated to a social protection health insurance scheme or beneficiary or beneficiary
Subject able to understand the objectives and risks related to the research and to give dated and signed informed consent
Disqualifiers
- Contraindication for performing a superficial skin biopsy provided for by the protocol
Molecular cause of parkinsonism previously identified
Absence of prior genetic exploration by high-throughput DNA sequencing
Patient with late-onset sporadic parkinsonian syndrome (> 40 years) without family history
Trial design
Treatments tested in this trial
- Combiner whole genome and RNA sequencing